结核病患者的曙光-氯法齐明

The 2020 Global Tuberculosis Report released by the WHO shows that an estimated 10 million people worldwide are suffering from tuberculosis in 2019, and approximately 500,000 people are suffering from rifampicin-resistant tuberculosis, of which approximately 78% are multidrug-resistant tuberculosis (MDR-TB). MDR-TB is still one of the current threats to global public health security, and China is still one of the countries with a high burden of tuberculosis in the world. It is an iminophenazine anti-tuberculosis drug. Its mechanism of action may compete with menadione (MK-4), a key cofactor in the electron transport chain of Mycobacterium tuberculosis, to be reduced by reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase. When reoxidized by O2, it releases active oxygen and plays a bactericidal effect. The drug has a very good effect on tuberculosis patients.

Mycobacterium, the infecting bacterium responsible for multidrug-resistant tuberculosis, can develop resistance to a variety of drugs. Clofazimine has a clinical effect on inhibiting Mycobacterium and has similar efficacy to conventional combination drugs in the fight against tuberculosis. Therefore, it has been clinically proposed that it should be used in conventional tuberculosis drugs. On the basis of drug therapy for multi-drug-resistant pulmonary tuberculosis, clofazimine is recommended for the treatment of multi-drug-resistant tuberculosis. Clofazimine and conventional tuberculosis drugs are recommended for the treatment of multi-drug-resistant tuberculosis. The treatment results show that the total effective rate of patients during the intensive period of treatment was (77.78%), and the negative conversion rate was (83.3%) ), the study can show that the clofazimine combination regimen can effectively improve the therapeutic efficacy in the treatment of multi-drug-resistant pulmonary tuberculosis and significantly improve the symptoms.

Observed in the study were nausea, abdominal pain, dry skin and ichthyosis-like changes, dizziness, drowsiness, loss of appetite, diarrhea, skin itching, hepatitis, upper gastrointestinal bleeding, splenic infarction, skin redness and pigmentation, intestinal obstruction, skin hypopigmentation, Aspen syndrome, vomiting, gastrointestinal bleeding, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.